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Aims: To date, suggestions that endothelin-1 (ET-1) causes nociception and pruritus are based on results in
preclinical models in which responses to pruritic and nociceptive stimuli cannot be distinguished. This
study reexamines these sensory effects of ET-1 in the new mouse cheek model, in which pruritogens and
algogens evoke distinct behavioral responses.
Main methods: Mice received intradermal (i.d.) injections of test substances into the left cheek and bouts of
hind limb scratches or forepaw wipes, directed to the injection site, were considered indicative of pruritus
and nociception, respectively.
Key ﬁndings: Histamine and capsaicin selectively evoked scratching and wipes, respectively, whereas ET-1
(3–60 pmol) promoted dose-dependent bouts of both behaviors. While scratching and wipe responses to
ET-1 (30 pmol) were potentiated by BQ-788 (an ETB receptor antagonist) and reduced by co-injection of
BQ-788 plus BQ-123 (an ETA receptor antagonist), BQ-123 alone inhibited scratching responses only. CTOP
(μ-opioid receptor selective antagonist) only augmented scratching responses to ET-1, whereas DAMGO
(μ-opioid receptor selective agonist) reduced both behaviors. Loratadine (histamine H1 receptor antagonist)
marginally reduced scratching, but markedly suppressed wipes.
Signiﬁcance: These results demonstrate that ET-1 evokes pruritic and nociceptive behaviors in the mouse
cheek model. Both responses to ET-1 appear to be mediated via ETA receptors and subjected to limitation
by simultaneous ETB receptor activation. Local endogenous opioids acting on μ-opioid receptors selectively
modulate the pruritic response to ET-1, whereas histamine, possibly derived from mast cells and acting on
H1 receptors, contributes importantly to the nociceptive effect of ET-1 in this model.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Itch (i.e. pruritus) is a cutaneous sensory modality different from
pain and a common symptom in dermatology and general medicine.
Recent elucidation of distinct pathways that convey sensory prurito-
ceptive information to the brain has enhanced our understanding of
its basis (Davidson and Giesler, 2010). Pruritus requires the activation
by pruritogenic stimuli of distinct subgroups of dedicated primary af-
ferent C-ﬁbers, one of mechano-insensitive/histamine-sensitive ﬁbers
(Schmelz et al., 1997) and another of histamine-insensitive non-
nociceptive polymodal ﬁbers (Imamachi et al., 2009; Sun et al.,
2009), but nociceptive polymodal ﬁbers are also involved.
Keratinocytes, leukocytes, mast cells, ﬁbroblasts, endothelial cells
and nerves in the skin produce several endogenous pruritogens, in-
cluding histamine, kinins, proteases, neurotrophins, some opioids
and cytokines (Ikoma et al., 2006). Many of them are also nociceptive
and complex functional interactions among them can exacerbate and
perpetuate itch sensation to promote chronic pruritic diseaseslogia, CCB - Bloco D, Universi-
Trindade, Florianópolis, Santa
: +55 48 3721 9813.
Y-NC-ND license.(Steinhoff et al., 2006; Metz and Ständer, 2010). Another potentially
relevant endogenous pruritogen produced by mast cells, endothelial
cells and keratinocytes in the skin is endothelin-1 (ET-1), a peptide
member of the endothelin family which activates speciﬁc G protein-
coupled ETA and ETB receptors to promote potent and diversiﬁed ef-
fects (Kedzierski and Yanagisawa, 2001).
In mice, ET-1 injection into the nape of the neck elicits ETA
receptor-mediated bouts of hind paw scratching directed to the
injected area (Trentin et al., 2006; McQueen et al., 2007). This effect
of ET-1 is signaled by ETA receptors possibly located on neurons ex-
pressing transient receptor potential vanilloid subfamily 1 (TRPV1)
receptors and coupled to adenylyl cyclase and protein kinase C path-
ways, but not to TRPV1 receptors themselves or phospholipase Cβ3
(Imamachi et al., 2009; Liang et al., 2010a). Scratching behavior in-
duced by ET-1 can be limited locally by activation of ETB receptors
(Trentin et al., 2006; Liang et al., 2010a) or transient receptor poten-
tial ankyrin subfamily member 1 (TRPA1) receptors (Liang et al.,
2011). However, if injected into a mouse's hind paw foot pad, ET-1 in-
duces licking behavior directed to the injected limb. This behavior is
interpreted as indicative of nociception, and is accompanied by sensi-
tization (i.e. hyperalgesia) to nociceptive effects of mechanical, ther-
mal and chemical stimuli (Piovezan et al., 2000; Baamonde et al.,
2004). ET-1-induced paw licking is also mediated by ETA receptors
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pathways (unlike scratching) involve phospholipase C activation, but
not protein kinase C (Liang et al., 2010b).
Many substances elicit back scratching bouts and hind paw licking
in animals. This usually is taken as evidence that they cause pruritus
at one locus and nociception at another. However, this interpretation
could be biased by the impossibility of mice to lick their backs or
scratch their hind paws. Recently, Shimada and LaMotte (2008) pro-
posed a new mouse cheek model which enables a clear-cut
behavior-based separation of pruritoceptive and/or nociceptive ef-
fects of substances. The present study sought to use this model to dis-
criminate the potential of ET-1 to induce pruritoceptive and




Experiments were conducted on male CD-1 mice (25–35 g), from
our own colony, lodged in a room with controlled temperature (22±
1 °C) and lighting (lights on from 06:00 to 18:00 h), with free access
to lab chow and tap water. All experimental procedures and protocols
were previously approved by the UFSC's committee on ethical use of
laboratory animals and are in accordance with Brazilian Legislation
and European Union's Directive 2010/63/EU.
Behavioral experiments
Pruritoceptive and nociceptive behaviors were evaluated in the
cheek model described by Shimada and LaMotte (2008), with minor
methodological modiﬁcations. Two days before the experimental pro-
cedure, animals were brieﬂy anesthetized with isoﬂurane (2% in 100%
oxygen) and the fur on both cheeks was shaved. On the day of the ex-
periment, each mouse was placed in an individual clear plastic con-
tainer (9 cm×9 cm×13 cm), ﬁtted with four angled mirrors to
enable complete unobstructed view of the subject at all times, and
left to habituate for 1 h before intradermal (i.d.) injection of a test
substance into the left cheek only.
As originally proposed by Shimada and LaMotte (2008), bouts of
single or repetitive back-and-forth scratching movements of the ipsi-
lateral hind limb directed to the injected cheek, followed by licking or
biting of the toes and/or placement of hind paw on the ﬂoor, were
counted and considered indicative of pruritoceptive behavior. Con-
versely, bouts of unilateral wipes of the ipsilateral forelimb directed
initially to the caudal portion of the injected cheek and proceeding
in a rostral direction, with the paw closed, were counted and consid-
ered indicative of nociceptive behavior.
Substances tested for their potential pruritoceptive/nociceptive
effects included: histamine (5, 10, 20 or 50 μg/site), capsaicin (1, 10
or 40 μg/site) or ET-1 (3, 10, 30 or 60 pmol/site), or an equal volume
of the vehicle (phosphate-buffered saline, PBS). These substances
were always injected intradermally (i.d.) in a volume of either 20 μl
(when tested alone) or 10 μl (when preceded by a given i.d. pretreat-
ment injection of similar volume, see cases below). The animals were
ﬁlmed, using a camcorder (Intelbras, model 200VM, Brazil) posi-
tioned in front of the container and connected to a computer, and
their pruritoceptive/nociceptive behaviors recorded continuously
over the ﬁrst 40 min after treatment, in 5-min bins.
To identify the receptors implicated in the effects of ET-1, mice
were given an i.d. injection of either BQ-123 (selective ETA receptor
antagonist), BQ-788 (selective ETB receptor antagonist; each at
10 nmol/site and in 10 μl) or a combination of both, 5 min prior to
i.d. injection of ET-1 (30 pmol/site) into the same cheek. To verify if
local mechanisms operated by μ-opioid receptors inﬂuenced the ef-
fects of ET-1, the peptide was injected (at 30 pmol/site) either aloneor in combination (i.e. co-injected) with the μ-opioid receptor selec-
tive antagonist CTOP (20 nmol/site) or agonist DAMGO (100 nmol/
site). Another set of experiments assessed the inﬂuence of intraperi-
toneal pretreatment (1 h beforehand) with the histamine H1 receptor
antagonist loratadine (10 mg/kg) on the effects of i.d. ET-1 (30 pmol/
site), in order to evaluate the contribution of endogenous histamine.
In all cases, control mice were always treated accordingly with iden-
tical volumes of the vehicle (PBS). The doses of all drugs used were
chosen on the basis of previous studies (Seike et al., 2005; Trentin
et al., 2006; Khodorova et al., 2009; Sun et al., 2009). Mice were tem-
porally removed from their containers for treatments and pretreat-
ments. Each animal was used only once and promptly sacriﬁced by
CO2 asphyxia in an acrylic chamber soon after termination of the
experiment.
Drugs
The following drugs were used: ET-1, BQ-123 (cyclo[DTrp-DAsp-
Pro-DVal-Leu]) and BQ-788 (N-cis-2,6-dimethylpiperidinocarbonyl-
L-γ-methylleucil-D-L-methoxycarboyl-D-norleucine) from American
Peptide Co. (Sunnyvale, CA, USA); capsaicin, histamine dichloride,
CTOP (D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-ornithyl-L-
threonyl-3-mercapto-L-valyl-,cyclic(2–7)-disulﬁde L-threoninamide),
DAMGO ([D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate) and lorata-
dine from Sigma Chemical Co. (St Louis, MO, USA). All drugs were dis-
solved in PBS.
Statistical analysis
All behavioral data are expressed as the mean±S.E.M. of six to
eight animals, and are presented either as the total number of
scratching or wiping bouts during the ﬁrst 40 min following injection
of the nociceptive/pruritoceptive compound, or in 5-min bins
throughout the observation period. Statistical comparisons were
made using one-way analysis of variance (ANOVA) followed by
Newman–Keuls post-hoc test. Differences with Pb0.05 were consid-
ered to be signiﬁcant.
Results
Histamine (5 to 50 μg/site) induced dose-dependent scratching
bouts (total events in 40 min: PBS 6.2±1.2 vs. histamine 50 μg/site
46.0±5.1, Pb0.05), but no wiping bouts (total events in 40 min:
PBS 5.0±2.1 vs. histamine 50 μg/site 12.9±3.0, P>0.05, N=6–8),
whereas capsaicin (1 to 40 μg/site) promoted dose-dependent wiping
bouts (total events in 40 min: PBS 11.1±2.5 vs. capsaicin 40 μg/site
60.2±10.1, Pb0.05), but no scratching bouts (total events in
40 min: PBS 9.0±3.6 vs. capsaicin 40 μg/site 5.3±2.1, P>0.05,
N=6–8). These results fully corroborate the original ﬁndings of
Shimada and LaMotte (2008) in the model.
Intradermal ET-1 injections (3 to 60 pmol/site) induced dose-
dependent bouts of scratching (Fig. 1A) and wiping (Fig. 1B). Both
pruritoceptive and nociceptive behaviors displayed rapid onsets
and occurred over the ﬁrst 20 min after injection (panel insets
show time-courses of the effects of ET-1 30 pmol/site, in 5-min
bins). As shown in Fig. 2, pretreatment with BQ-123 (10 nmol/site)
markedly reduced the incidence of scratching bouts (pruritus; 89%
inhibition) induced by ET-1 (30 pmol/site), but not that of wipes
(nociception). In contrast, BQ-788 augmented both effects of ET-1
substantially (scratching and wiping bouts were potentiated by
72% and 108%, respectively). Co-injection of both ETA and ETB recep-
tor antagonists resulted in signiﬁcant attenuation of both responses
when compared to those induced by ET-1 in cheeks pretreated
with BQ-788 alone (Fig. 2). Importantly, neither BQ-123 nor BQ-
788 affected pruritic or nociceptive responses of PBS-treated control
mice.
Fig. 1. Injection of ET-1 into the cheek evokes pruritic and nociceptive behaviors in
mice. Histograms indicate the total number of scratching (A) and wiping (B) bouts
observed over the ﬁrst 40 min after i.d. injection of ET-1 at the doses indicated or
PBS. The insets show the time-courses of each behavioral response to ET-1
(30 pmol), in 5-min bins. Values represent the mean±SEM of 6–8 animals.
Asterisks denote Pb0.05 when compared to the corresponding value of PBS-treated
animals (ANOVA followed by Newman–Keuls test).
Fig. 2. Inﬂuence of ETA or ETB receptor antagonists on scratching (A) and wiping (B)
behaviors induced by ET-1 in the cheek. BQ-123 (ETA receptor antagonist), BQ-788
(ETB receptor antagonist), both antagonists (BQ-123+BQ-788; each at 10 nmol) or
PBS were injected into the left cheek 5 min before i.d. injection of ET-1 (30 pmol) or
PBS into the same cheek. Values represent the mean±SEM of 6–8 animals. Asterisks,
fences and φ denote Pb0.05 relative to groups treated with PBS+PBS, ET-1+PBS or
ET-1+BQ-788, respectively (ANOVA followed by Newman–Keuls test).
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ceptive effect of ET-1 (10 pmol/site) by 60%, but the nociceptive ef-
fects of the peptide were unaffected by this selective μ-opioid
receptor antagonist (Fig. 3). Nonetheless, the selective agonist of μ-
opioid receptors DAMGO (100 nmol/site) reduced both behavioral re-
sponses to ET-1, inhibiting scratching and wiping bouts by 50% and
87%, respectively. Basal responses of vehicle-treated controls were
not modiﬁed by co-administration of CTPO or DAMGO.
Systemic pretreatment with the histamine H1 receptor antagonist
loratadine (10 mg/kg) signiﬁcantly reduced both effects of ET-1, but
scratching bouts were inhibited to a lesser extent than wiping bouts
(22% and 61% inhibition, respectively; Fig. 4). Loratadine did not mod-
ify the responses of PBS-treated control mice.
Discussion
Humans can accurately discriminate itch from pain and report on
the relative intensities at which many stimuli evoke these sensations.
In contrast, preclinical behavior-based models to characterize pruritic
and/or nociceptive effects of substances or procedures are subjected
to the potential bias of assuming that the behaviors measured are
speciﬁc responses to pruritus or nociception. For example, humansreport that i.d. injections of histamine and capsaicin cause itch and
pain, respectively, but when these substances are injected into the
nape of the neck of mice, they both evoke bouts of hind limb scratch-
ing directed to the injection site, a behavior interpreted as indicative
of pruritoception (Shimada and LaMotte, 2008). However, by chang-
ing the site of injection of these substances to the cheek, the authors
could clearly distinguish the bouts of hind limb scratching (pruritus)
evoked by histamine from the bouts of forepaw wipes (nociception)
induced by capsaicin.
Previous studies concluded that ET-1 displays pruritoceptive and
nociceptive properties, based on its ability to induce back scratching
and paw licking behaviors, respectively. The main contribution of
the current study is that it demonstrates, to our knowledge for the
ﬁrst time, that ET-1 indeed evokes unbiased dose-dependent behav-
ioral responses suggestive of both pruritus and nociception in the
mouse cheek model, alongside results which fully conﬁrm the clear-
cut distinct behavioral effects of histamine and capsaicin originally
reported by Shimada and LaMotte (2008).
Using this same cheek model, Akiyama et al. (2010a,b) found that
agonists of protease-activated receptor subtypes PAR-2 and PAR-4
and the anti-malarial drug chloroquine elicit mainly bouts of hind
limb scratching, whereas bradykinin and the TRPA1 receptor agonist
allyl isothiocyanate selectively evoke bouts of forelimb wipes. Inter-
estingly, those studies also reported that serotonin, cowhage spicules
and formalin promote approximately equal amounts of both types of
behavior. Thus, ET-1 appears to belong to a category of substances
Fig. 3. Inﬂuence of μ-opioid receptor-mediated mechanisms on scratching (A, B) and wiping (C, D) behaviors induced by ET-1 in the cheek. The selective μ-receptor antagonist CTOP
(20 nmol; in A and C) or agonist DAMGO (100 nmol; in B and D) were co-injected together with either ET-1 (30 pmol, i.d.) or PBS. Values represent the mean±SEM of 6–8 animals.
Asterisks and fences denote Pb0.05 relative to groups treated with PBS+PBS or to ET-1+PBS, respectively (ANOVA followed by Newman–Keuls test).
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fact that volunteers receiving i.d. injections of ET-1 into the forearm
report a sensation of burning pruritus (Ferreira et al., 1989) further
substantiates the validity of the cheek model in behaviorally discrim-
inating both components and its potential in reproducing the sensory
effects the peptide promotes in humans.
The current study shows that local treatment of the cheek with the
ETA receptor antagonist BQ-123 markedly reduced the pruritic effects
of ET-1, without modifying signiﬁcantly its nociceptive effects. In-
deed, scratching induced by ET-1 was also found to be mediated by
ETA receptors in the nape of the neck model (Trentin et al., 2006;
McQueen et al., 2007; Liang et al., 2010a). The failure of ETA receptor
blockade to inhibit the nociceptive effect of ET-1 in the cheek was
rather unexpected, as previous studies had shown that BQ-123 re-
duces ET-1-induced hind paw licking in mice (Piovezan et al., 2000;
Menéndez et al., 2003) or hind paw ﬂinches in rats (Khodorova et
al., 2003). However, contrasting the reported lack of effect of the
ETB receptor antagonist BQ-788 against ET-1-induced hind paw lick-
ing in mice (Piovezan et al., 2000; Menéndez et al., 2003), we ob-
served that both nociceptive and pruritoceptive responses to
injection of ET-1 in the cheek were increased following local treat-
ment with this antagonist. Back scratching induced in mice by ET-1
injection into the nape of the neck was also found to be potentiated
by BQ-788 and reduced by co-injection with an ETB receptor agonist
(Trentin et al., 2006; Liang et al., 2010a), but another study (using a
different strain of mice) failed to conﬁrm an anti-pruritic role for
ETB receptors in that model (McQueen et al., 2007). On the other
hand, it is noteworthy that co-injection of BQ-123 together with
BQ-788 signiﬁcantly reduced both the pruritoceptive and nociceptive
effects of ET-1 in the cheek model, relative to the (augmented) re-
sponses the peptide induced following BQ-788 treatment alone. Weinterpret these results as evidence that ETA receptors mediate both
effects of ET-1 in the cheek model, even if the nociceptive response
to ET-1 following combined antagonist (BQ-123 plus BQ-788) treat-
ment was not signiﬁcantly different from the one it induced on its
own. This view is strengthened by reports that ETB receptors exert
an anti-hyperalgesic effect in the mouse hind paw against nocicep-
tion induced by capsaicin, heat or cancerous cells (Piovezan et al.,
2000; Baamonde et al., 2004; Quang and Schmidt, 2010) and also
limit ET-1-induced ETA receptor-mediated hind paw ﬂinching in rats
(Khodorova et al., 2003).
Itch may be inversely related to pain because it is a common side-
effect of centrally-administered opioids and is reduced by nociceptive
counter-stimuli such as vigorous scratching (Szarvas et al., 2003). On
the other hand, the nociceptive effect of ET-1 in the rat hind paw is
limited by activation of ETB receptors on skin keratinocytes coupled
to release of β-endorphin, which in turn activates antinociceptive μ-
opioid receptors on the nociceptive sensory ﬁbers (Khodorova et al.,
2003). Moreover, i.d. injection into the nape of the neck of lopera-
mide, morphine or the selective μ-opioid receptor agonists fentanyl
and DAMGO can each cause scratching behavior in mice (Yamamoto
and Sugimoto, 2010; Yamamoto et al., 2010). In contrast, i.d. injection
of morphine into the cheek fails to promote scratching behavior in
mice (Kuraishi et al., 2000). We thus tested the effects of i.d. injec-
tions of the selective μ-opioid receptor antagonist CTOP and agonist
DAMGO, at doses not affecting responses of PBS-treated control
mice, on the pruritic and nociceptive behaviors evoked by ET-1.
CTOP increased the number of scratching bouts induced by ET-1,
but not of wiping bouts. This could suggest that μ-opioid receptors ac-
tivated locally by endogenous opioids only inhibit the pruritic effects
of ET-1 in the cheek. However, this does not appear to be the case, as
we observed that DAMGO reduced both types of behavior evoked by
Fig. 4. Inﬂuence of the histamine H1 receptor antagonist loratadine on scratching (A)
and wiping (B) behaviors induced by ET-1 in the cheek. Mice were given an intraper-
itoneal injection of loratadine (10 mg/kg) or PBS 1 h before i.d. injection of ET-1
(30 pmol) or PBS into the left cheek. Values represent the mean±SEM of 6–8 ani-
mals. Asterisks and fences denote Pb0.05 relative to groups treated with PBS+PBS
or ET-1+PBS, respectively (ANOVA followed by Newman–Keuls test).
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neous) injection of morphine does not modify scratching induced
by ET-1 in the nape of the neck model (Liang et al., 2011). Thus, it
may be that in the cheek, which is innervated by the trigeminal sys-
tem, pruritus can suppress nociception, i.e. the opposite to what oc-
curs in other body regions. Clearly further studies are needed to
better understand the relations between both sensory modalities in
this new model, as well as their modulation by mechanisms signaled
locally by the endogenous opioids present and the receptor subtypes
they activate.
Besides evoking a sensation of burning pruritus (Ferreira et al.,
1989), injection of ET-1 into the forearm of volunteers also induces
a wheal and ﬂare response which is reduced by treatment with hista-
mine H1 receptors antagonists, but fails to release histamine from
human acutely dispersed skin mast cells (Brain et al., 1992). Other
studies, however, have shown that ET-1 can induce degranulation of
peritoneal mast cells (Yamamura et al., 1994; Maurer et al., 2004).
On the other hand, nociception induced by ET-1 in the mouse hind
paw is markedly reduced by depletion of local resident mast cells
(Rae et al., 2001), but its ability to evoke scratching behavior in the
nape of the neck seems independent of histamine-mediated signaling
mechanisms (Imamachi et al., 2009). The current study demonstrates
that, in the cheek model, systemic treatment with the histamine H1
receptor antagonist loratadine markedly suppressed bouts of forepaw
wipes evoked by ET-1, while inhibiting only slightly (albeit signiﬁ-
cantly) the bouts of hind limb scratching induced by the peptide.
These ﬁndings indicate that histamine, possibly released from mast
cells and acting via H1 receptors, contributes importantly to the noci-
ceptive effects of ET-1, but plays a minor role in its pruritic effect.
The results of the current study show that ET-1 evokes distinct
pruritic and nociceptive behaviors in the mouse cheek. These ﬁndingsessentially conﬁrm, in a single model, previous reports that the pep-
tide elicited behaviors suggestive of either one or the other type of
sensation, depending on the behavioral model used. Considering
that ET-1 can be produced in the skin by mast cells, keratinocytes
and endothelial cells, perhaps this experimental model could be use-
ful to investigate the contribution of endogenous ET-1 to alterations
in the pruritoceptive and nociceptive mechanisms associated with
skin inﬂammation.
Conclusion
The results of the current study demonstrate that i.d. ET-1 in-
jection into the cheek of the mouse evokes two distinct behavior-
al responses which are indicative of pruritus and nociception.
Both effects of ET-1 are mediated via ETA receptors and limited
by simultaneous activation of ETB receptors. Endogenous opioids
acting on μ-opioid receptors inhibit only the pruritoceptive effect
of ET-1. Conversely, histamine, acting on H1 receptors, seems to
contribute importantly to the nociceptive effect of ET-1, but less
so to its pruritoceptive effect.Conﬂict of interest statement
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